Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following gains on Monday.

The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...

Novo Nordisk shares staged a dramatic rebound on Monday, recovering 8% after a steep 20% plunge on Friday. The recovery was ...

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, ...

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...

Few companies have broken into the public’s consciousness as thoroughly as Novo Nordisk has over the past couple of years. Its Wegovy weight-loss drug and Ozempic diabetes treatment are so ...

Registered shareholders who are residents of Canada as reflected in the Company’s shareholders register, as well as beneficial Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) ...

Previous studies sponsored by Lilly and Novo Nordisk found that each of the drugs helped people who are obese lose significant amounts of weight, but those trials didn’t compare Zepbound and ...